Volitionrx Limited · AMEX:VNRX
Volitionrx — FY2021 Earnings Presentation
30 slides from Volitionrx's earnings presentation, March 2022
Slide 1: 2021 Financial Results & Business Update
2021 Financial Results & Business Update March 2022 Property of Volition© 2022 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptio
Slide 3: Welcome
Welcome Volition Veterinary Diagnostics© 2019 Property of Volition 2022 © Confidential Slide 3
Slide 4: Volition Veterinary Diagnostics Development
Property of Volition Veterinary Diagnostics Development © 2022 Slide 4
Slide 5: A little background
A little background • Personal involvement • MOU with Texas A&M University April 2019 • Volition Veterinary Diagnostics Development LLC formed August 2019 • Contract signed with Texas A&M University October 2019 • Pre-analytics study presented at VCS 2019 • Clinical study presented at VCS 2020 • Pee
Slide 6: The Deal: Heska
The Deal Heska • is a leading global provider of advanced veterinary diagnostics. • is dedicated to developing the next generation of rapid, low-cost, point-of-care diagnostics for companion animals. • has a worldwide distribution and partnering network. • shares our philosophy, our work ethic and v
Slide 7: The Deal: Heska agreement terms
The Deal Our executed agreement provides Heska • Exclusive rights to sell Volition’s Nu.Q® Vet Cancer Test for companion animals at the point of care. • Non-exclusive rights to sell the Nu.Q® Vet Cancer Test for companion animals via Heska’s reference laboratories and, • Exclusive rights to canine c
Slide 8: The Deal: SAGE
The Deal Our executed agreement provides SAGE • Non-exclusive rights to sell Volition’s Nu.Q® Vet Cancer Test for companion animals in centralized labs in Singapore, • followed by expansion in conjunction with SAGE Healthcare into centralized labs in other key Asian markets. • Launch preparations at
Slide 9: Other deals?
Other deals? • In advanced negotiations with other potential licensing partners • ……. so please watch this space for further details in 2022. Property of Volition Veterinary Diagnostics Development © 2022 Slide 9
Slide 10: New Team Members
New Team Members Daniel Sheres Devin DeVoue Kristy Valdivia Product Manager Marketing Manager Global Accounts Manager Property of Volition Veterinary Diagnostics Development © 2022 Slide 10
Slide 11: Looking ahead
Looking ahead • Further licensing deals • Cat collection underway • Busy conference schedule Property of Volition Veterinary Diagnostics Development © 2022 Slide 11
Slide 12: Thank you for your interest
Thank you for your interest…… …..significant opportunity Property of Volition Veterinary Diagnostics Development © 2022 Slide 12
Slide 13: Update
Update Property of Volition© 2022 Slide 13
Slide 14: New Team Members
New Team Members Dr. Gaetan Michel Dr. Tom Butera Chief Operating Officer Terig Hughes, Chief Executive Officer VVDD Director, VVDD Group Chief Financial Officer Gael Forterre, Dr. Terry Kelly Nick Plummer Chief Commercial Officer Chief Innovation Officer Group General Counsel Property of Volition©
Slide 15: What sets us apart?
What sets us apart? 29 patent Our key differentiator is our Intellectual Property families* 84 patents pending worldwide* • Our patent portfolio is growing 58 additional patents granted worldwide in • Our products are protected until at least 2031 growing IP including animal diagnostics portfolio* 1
Slide 16: Developing a diagnostic solution for NETosis
Developing a diagnostic solution for NETosis An abnormal immune response Property of Volition© 2022 Slide 16
Slide 17: NETs Update
NETs Update • Wide applicability for monitoring diseases with a NETs component (e.g.COVID-19, influenza, sepsis, autoimmune diseases & cancer) • Data published show that the level of circulating NETs, as measured using our Nu.Q ® NETs assays, correlates with current disease severity and mortality in
Slide 18: Nu.Q Discover
Nu.Q® Discover • Nu.Q® Discover gives clinicians, patients, and researchers access to a range of state-of-the-art assays, built on our proprietary Nucleosomics™ platform, for rapid epigenetic profiling in disease model development, preclinical testing and clinical trials. • Existing and potential cu
Slide 19: Nu.Q Discover Market Opportunity
Nu.Q® Discover Market Opportunity • Total Addressable Market for Nu.Q® Discover over $200 million per annum worldwide* • This opportunity is calculated using • publicly available drug pipeline data, • number of clinical trials and • average failure rates for relevant epigenetic targets. • On average
Slide 20: Finance Update
Finance Update Property of Volition© 2022 Slide 20
Slide 21: Finance Update
Finance Update • Cash & Cash Equivalents $20.6 million as of December 31, 2021 • Jan 2021 Non-Dilutive Funding of $4 million • Feb 2021 Underwritten public offering raising Net Proceeds $18.9 million • $4.6 million raised through At-the-Market equity distribution program • Underlying cash burn $2 mi
Slide 22: Profit & Loss Account
Profit & Loss Account Full year Net Loss $27 million versus $20.4 million Net Loss PY • R&D Spend $15.5 million • General & Admin $8.8 million including one-off non-cash item • Sales & Marketing $4.1 million • Grant Income $1.5 million • Modest revenue of $90,000 Property of Volition© 2022 Slide 22
Slide 23: Subsequent Event
Subsequent Event Under the Heska agreement Volition will receive: • an upfront payment of $10 million dollars; • up to $18M based upon the achievement of near and mid-term milestones, and • payment for kits and key components at pre-agreed prices which we expect will provide a significant future rev
Slide 24: $70 billion Total Addressable Market
Total Addressable Market $70 billion* *subject to fluctuations based on numerous assumptions, which, if prove incorrect could materially impact our estimations andresults. Property of Volition© 2022 Slide 24
Slide 25: Nu.Q Vet, Discover, NETs and Cancer markets
Nu.Q® Vet • approximately $11 billion* per annum worldwide • based on global canine and feline populations that are eligible for screening and monitoring • and a price assumption of $50 per test to the consumer Nu.Q® Discover • >$200 million* per annum worldwide • based on drug pipeline data of regi
Slide 26: Update
Update Property of Volition© 2022 Slide 26
Slide 27: Nu.Q Cancer Update
Nu.Q® Cancer Update • Anticipate NHL study Q2 2022 • EDRN re-initiated enrollment in June 21 and estimates completion Dec 22 • NTU • Colorectal cancer data presented at ASCO GI Jan 22 • Lung data submitted Property of Volition© 2022 Slide 27
Slide 28: Property of Volition © 2022 Slide 28
Property of Volition© 2022 Slide 28
Slide 29: Nu.Q Capture: Transformational Technology
Nu.Q® Capture: Transformational Technology Several Strands • essentially remove background noise • look to identify the signal in a novel way. • aim to isolate various chromatin fragments including nucleosomes and transcription factors from plasma • for analysis by mass spectrometry and next-generat
Slide 30: In Conclusion
In Conclusion Property of Volition© 2022 Slide 30